Aerobic exercise induces cardiac fat loss and alters cardiac muscle mass through an interleukin-6 receptor–dependent mechanism: cardiac analysis of a double-blind …
RH Christensen, LL Lehrskov, AS Wedell-Neergaard… - Circulation, 2019 - Am Heart Assoc
RH Christensen, LL Lehrskov, AS Wedell-Neergaard, GE Legaard, M Ried-Larsen…
Circulation, 2019•Am Heart AssocAlthough not significant, total body weight showed similar tendencies and was reduced by
1.5 kg (95% CI,− 0.2 to 3.2; P= 0.079) more in the exercise+ placebo group compared with
the exercise+ tocilizumab group. The same was the case with PAT mass (11 g [95% CI,− 15
to 37], P= 0.41;≈ 17%[95% CI, 0–34], P= 0.049) for exercise+ placebo versus exercise+
tocilizumab, respectively (Figure, C). PAT was increased in the no exercise+ tocilizumab
group (28 g [95% CI, 9–47];≈ 22%[95% CI, 9–34]) but not in the no exercise+ placebo …
1.5 kg (95% CI,− 0.2 to 3.2; P= 0.079) more in the exercise+ placebo group compared with
the exercise+ tocilizumab group. The same was the case with PAT mass (11 g [95% CI,− 15
to 37], P= 0.41;≈ 17%[95% CI, 0–34], P= 0.049) for exercise+ placebo versus exercise+
tocilizumab, respectively (Figure, C). PAT was increased in the no exercise+ tocilizumab
group (28 g [95% CI, 9–47];≈ 22%[95% CI, 9–34]) but not in the no exercise+ placebo …
Although not significant, total body weight showed similar tendencies and was reduced by 1.5 kg (95% CI,− 0.2 to 3.2; P= 0.079) more in the exercise+ placebo group compared with the exercise+ tocilizumab group. The same was the case with PAT mass (11 g [95% CI,− 15 to 37], P= 0.41;≈ 17%[95% CI, 0–34], P= 0.049) for exercise+ placebo versus exercise+ tocilizumab, respectively (Figure, C).
PAT was increased in the no exercise+ tocilizumab group (28 g [95% CI, 9–47];≈ 22%[95% CI, 9–34]) but not in the no exercise+ placebo group (− 12 g [95% CI,− 31 to 7] or 0%[95% CI,− 13 to 12]), rendering a difference in PAT between these groups of 40 g (95% CI, 13–67, P= 0.004;≈ 22%[95% CI, 4–40],
Am Heart Assoc
